Suggestions
Marco Ruella
Assistant Professor Of Medicine and Scientific Director Lymphoma Program
Marco Ruella is an accomplished physician-scientist and Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies at the University of Pennsylvania.13 Here are some key details about Dr. Ruella:
Education and Training
Dr. Ruella obtained his medical degree with high honors from the University of Torino, Italy, where he also completed his specialization in clinical hematology.1 He later pursued postdoctoral training at the University of Pennsylvania, working in the Center for Cellular Immunotherapies under Drs. June and Gill.1
Current Positions
- Assistant Professor of Medicine at the University of Pennsylvania (since 2018)13
- Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania13
- Attending Physician at the Hospital of the University of Pennsylvania (since 2019)2
Research Focus
Dr. Ruella's research primarily focuses on:
- Studying mechanisms of relapse after chimeric antigen receptor T cell (CAR-T) immunotherapies3
- Developing innovative immunotherapies for relapsing/refractory leukemia and lymphoma3
Achievements and Recognition
Dr. Ruella has received numerous awards for his work, including:
- SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014)1
- AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015)1
- ASH Scholar Award (2016)1
- NIH K99-R00 award (2017)1
- ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement (2018)1
He is also an inventor on several patents related to CAR-T therapy and has authored numerous peer-reviewed publications on targeted immunotherapies for hematological cancers.13
Highlights
Our letter to the NEJM Group reporting the five-year outcomes of CART19 (CTL019, now called tisagenlecleucel) in lymphoma patients is out! Thanks to Drs. Schuster and Chong and University of Pennsylvania Carl June Bruce Levine Stephen Schuster
Post-doctoral Fellow Position Available!
The Ruella laboratory at the University of Pennsylvania is seeking post-doctoral fellows to study the mechanisms of relapse after Chimeric Antigen Receptor T Cell immunotherapy and develop novel CART therapies. We have laboratory, clinical, and correlative research projects available! Check our research, here:
https://lnkd.in/dWJtRxn
Backgrounds in immunology and/or hematology preferred. Applicants with backgrounds in protein engineering, cancer biology, molecular biology, and genome engineering who have a research interest in immunology are also encouraged to apply. Applicants should have an M.D. or Ph.D. or equivalent doctoral degree. The ideal candidate should have an excellent publication record, be able to work independently and in a team, and be prepared to supervise students and technicians.
Payment is according to the NIH pay scale. UPenn is an equal opportunity/affirmative action employer. All qualified candidates are encouraged to apply. Please submit complete application documents (including CV with publication list, and references) via email to: [email protected] #upenn #universityofpennsylvania #cartcelltherapy #postdoc #hiringduringcovid
